Elizabeth McKenna: New Cancer Grand Challenges Teams Announced
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
AI Summary: Global funders announced new Cancer Grand Challenges awards, backing five international teams with large, high‑risk grants to pursue transformative cancer science. The initiative aims to accelerate unconventional, high‑reward projects and foster cross‑disciplinary collaboration — essentially underwriting audacity in hopes that at least one risky bet pays off.
CART19-BE-02 trial: From Bench to Bedside and Beyond – Resonance
oncodaily - ALRCaN presents “CART19-BE-02 trial: From Bench to Bedside and Beyond—Implementing a Hospital-Based CAR T Program and Integrating It into the Spanish NHS” with Dr. Valentín Ortiz-Maldonado. “Dear friends and colleagues, […]
AI Summary: Bereaved relatives delivered searing final testimonies as the Covid inquiry wound up four years of public hearings, recounting loved ones who died alone and demanding answers. Chair Baroness Heather Hallett defended the process and its roughly £200 million price tag as necessary to finish the work, despite public frustration and political scrutiny.
Telehealth growth hasn’t increased rural behavioral healthcare access: Study
Giles Bruce / beckershospitalreview - The rise in telemedicine over the past several years hasn’t translated to more behavioral healthcare access in rural areas, according to a March 5 study in JAMA Network Open. Researchers from Boston-based Harvard Medical School and Providence, R.I.-based …
AI Summary: A new study finds the rapid expansion of telemedicine did not meaningfully improve access to behavioral health services in rural areas. Persistent barriers—workforce shortages, broadband gaps, and reimbursement limits—keep telehealth from being the miracle fix some hoped for. Turns out, high-speed internet isn’t a therapist.
New FDA bonus pilot to address 'workforce challenges'
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
AI Summary: The FDA has introduced a pilot program offering performance bonuses to expedite regulatory reviews, aiming to tackle reviewer workload and improve timeliness. Funded partly by industry user fees, the initiative seeks to reward faster, high‑quality reviews while balancing independence and efficiency—proof that carrots sometimes replace the endless stick of overtime.
Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC
Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.
AI Summary: Federal regulators and two pharmacy benefit managers are reportedly making substantial progress toward resolving an FTC antitrust probe tied to insulin pricing and PBM practices. Negotiations aim to settle allegations without protracted litigation, potentially changing how PBMs operate and how insulin costs are managed for states and patients.
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
AI Summary: Moderna has agreed to settle long-running patent disputes over its COVID-19 vaccine technology for up to $2.25 billion, resolving litigation with several claimants. The deal provides Moderna with broad licensing rights and clears a major legal uncertainty, allowing the company to move forward without another courtroom cliffhanger.
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.
Hospitals urge regulators to halt drugmakers’ expanded 340B data policies
Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
AI Summary: Hospitals and provider groups are urging federal regulators to halt new drugmaker policies that expand claims-data reporting tied to 340B discounts, calling the requirements unlawful and administratively burdensome. The dispute pits safety-net providers against manufacturers seeking program transparency — a classic tug-of-war with patients’ financial stakes caught in the middle.
AI blood test finds silent liver disease years before symptoms
sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…
AI Summary: Researchers unveiled an AI‑driven liquid biopsy that scans genome‑wide cell‑free DNA fragment patterns to flag liver fibrosis, cirrhosis and chronic liver disease well before symptoms appear. Early results indicate the test can identify disease signals years ahead of clinical diagnosis, offering a shot at much earlier intervention — if practice and payers cooperate.
Amazon launches Amazon Connect Health
Naomi Diaz / beckershospitalreview - Amazon Web Services has launched Amazon Connect Health, an artificial intelligence tool designed to automate administrative tasks for health systems and improve patient access to care. Here are six things to know about Amazon Connect Health: Amazon Connec…
AI Summary: Amazon Web Services rolled out a suite of agentic AI tools under the Amazon Connect Health name to take on the administrative drudgery of healthcare — scheduling, ambient note‑taking, coding and patient engagement. The platform promises to automate front‑office tasks, generate clinical summaries, and integrate with provider workflows, aiming to free clinicians from endless paperwork.
Novo Nordisk inks $2.1B oral obesity drug deal
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.
Novartis closes Avidity deal as rare heart disease spinout launches
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
AI Summary: Novartis completed its Avidity Biosciences transaction and backed the launch of Atrium Therapeutics, a newly funded spinout focused on RNA therapies for rare cardiac conditions. Atrium inherits delivery platforms and early programs with substantial capital, as Novartis reshuffles assets to accelerate its RNA strategy — because apparently doubling down on hot modalities never gets old.
After 4-Week Strike, Kaiser Permanente Workers Score Tentative Win on Staffing & Pay
Katie Adams / medcitynews - About 31,000 Kaiser Permanente workers ended a four-week strike after reaching a tentative agreement that includes measures to address chronic understaffing and wage increases. The full contract has not yet been ratified.The post After 4-Week Strike, Kais…
AI Summary: After a four‑week strike, roughly 31,000 Kaiser Permanente workers reached a tentative agreement that includes commitments on staffing levels and compensation. The deal ends a major labor standoff that had disrupted services and put pressure on management to address long‑standing workforce concerns.
Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
AI Summary: Merck reorganized its Human Health structure to form a separate oncology business unit, positioning the company to defend and optimize its cancer franchise ahead of Keytruda patent pressures and to sharpen focus across therapeutic areas as part of a broader commercial realignment.
Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model
fiercehealthcare - Teladoc Health reported better-than-expected fourth quarter financial results with both revenue and earnings exceeding analysts' expectations, driving a 15% jump in the company's stock Thursday.
AI Summary: Telehealth provider Teladoc reported slower growth and issued a cautious outlook as it shifts its telehealth model, warning of membership headwinds and potential declines in integrated‑care enrollment tied to market dynamics and policy changes. Management signaled strategic recalibration to stabilize long‑term performance.
CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health
fiercehealthcare - Elevance Health Chief Financial Officer Mark Kaye will grow his list of duties to include oversight of Carelon, the company announced Thursday.
AI Summary: Elevance Health elevated CFO Mark Kaye to take expanded responsibility overseeing Carelon as part of a broader C-suite reshuffle. The reorganization centralizes oversight of the company’s growth arm and signals a tighter alignment between payer operations and its care-management business amid strategic and operational realignments.
Novartis to build $23B radioligand therapy site
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
AI Summary: Novartis announced plans to construct a 46,000‑square‑foot radioligand therapy manufacturing facility in Denton, Texas, part of a broader $23 billion U.S. expansion. The site aims to boost domestic production capacity for targeted radiopharmaceuticals, signaling Big Pharma’s bet that radioligand therapies will be a growth engine — and a lovely way to justify large real estate footprints.
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
AI Summary: Generate Biomedicines priced a U.S. IPO at $16 per share, selling 25 million shares and raising about $400 million to advance AI-designed drugs — notably a less-frequent injection candidate for severe asthma. The offering renews investor appetite for AI-driven biotech and funds pivotal clinical work, while whispering about a lofty post-listing valuation.
UHS posts 11.5% operating margin in 2025 as net income jumps 30%
Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services recorded a net income of $1.5 billion in 2025, up from $1.1 billion in 2024, according to its Feb. 25 financial report. Eight things to know: 1. The for-profit system reported an operating income of $2 …
AI Summary: Universal Health Services reported robust 2025 financial results and outlined an optimistic 2026 outlook, driven by acute and behavioral health operations. Leadership flagged growth targets for admissions and behavioral services even as staffing and regulatory pressures persist — the usual blend of confidence and contingency planning.